Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
Open Access
- 13 August 2009
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 65 (6), 1023-1028
- https://doi.org/10.1007/s00280-009-1107-5
Abstract
Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. The purpose of this study is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as first-line treatment and subsequent salvage treatment with erlotinib. A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 12 (57.1%) patients with salvage erlotinib. There was an association between the disease control with gefitinib and erlotinib (p = 0.031). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib.Keywords
This publication has 32 references indexed in Scilit:
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)Journal of Clinical Oncology, 2011
- Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to GefitinibClinical Cancer Research, 2008
- Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatmentAnnals Of Oncology, 2008
- Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancerBMC Cancer, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancerLung Cancer, 2005
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2005
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000